Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
InteKrin
company
About
InteKrin Therapeutics is focused on developing and commercializing therapeutics for neuroendocrine, metabolic and immune disorders.
- 1 - 10
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $18.50M
- Industries
- Biotechnology,Neuroscience,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 1 - 10
- Operating Status
- Close
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$41.95M
InteKrin has raised a total of
$41.95M
in funding over 2 rounds. Their latest funding was raised on
Aug 4, 2008 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 4, 2008 | Series C | $18.50M | 1 | — | — | Detail |
| Jan 12, 2007 | Series B | $23M | 1 | — | — | Detail |
| Sep 22, 2006 | Debt Financing | $450K | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
InteKrin is funded by 2 investors.
Sears Capital Management
and Asset Management Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sears Capital Management
|
— | Series C |
Asset Management Partners
|
— | Debt Financing |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
